Press Releases

Resolution and Reduction Of Past Billings & Pending Stock Issuances and New DCVax®-Direct Manufacturing Agreement BETHESDA, MD., May 28, 2019  Northwest Biotherapeutics (NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement agreement with Cognate BioServices, Inc., resolving past matters and providing for restart of... Read More

31 Years Managing Portfolios At Several Major Wall Street Firms, With Emphasis On Biotech BETHESDA, MD, February 26, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has hired David Innes as Vice President, Investor Relations. Innes comes to NW Bio with over 31 years of managing portfolios at major... Read More

BETHESDA, Md., February 8, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the final voting results from the Annual Shareholder Meeting held on February 2, 2019. Votes were cast by 460,778,696 (88.7%) of the total 519,729,780 shares that were issued and outstanding on the record date of December 13, 2018, and as such... Read More

Focus on Complexity and Variability of Solid Tumors, and How DCVax®-L Addresses Them BETHESDA, Md., January 25, 2019 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, presented at the Phacilitate Leaders World 2019 Conference in Miami, Florida. The slide deck from this presentation can be... Read More

BETHESDA, Md., December 14, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the package transaction involving the Company’s UK property, which the Company announced earlier this week, closed today in the UK. The closing included the transaction elements previously announced: The funding of approximately... Read More